Lensar (LNSR) Total Non-Current Liabilities (2019 - 2026)
Lensar's (LNSR) quarterly Total Non-Current Liabilities came in at $40.8 million in Q1 2026, down 49.4% year-on-year from $80.7 million in Q1 2025, and down 50.66% on a QoQ basis from $82.8 million in Q4 2025.
Lensar (LNSR) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Lensar (LNSR) has 8 years of Total Non-Current Liabilities data on file, last reported at $40.8 million in Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities fell 49.4% year-over-year to $40.8 million in Q1 2026; TTM through Mar 2026 was $40.8 million, a 49.4% decrease from a year earlier, with the FY2025 full-year figure at $82.8 million, up 365.05% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $40.8 million, down from $82.8 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for LNSR reached as high as $82.8 million in Q4 2025 and fell as low as $10.4 million in Q1 2022.
- Historically, Total Non-Current Liabilities has averaged $30.2 million across 5 years, with a median of $20.0 million in 2024.
- Across the five-year window, Total Non-Current Liabilities jumped 516.69% in 2025 and tumbled 49.4% in 2026, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $13.7 million in 2022, then gained by 1.89% to $14.0 million in 2023, then advanced by 27.54% to $17.8 million in 2024, then surged by 365.05% to $82.8 million in 2025, then slumped by 50.66% to $40.8 million in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $40.8 million in Q1 2026, $82.8 million in Q4 2025, and $81.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 20.94 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 41.44 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 41.88 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 2.64 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 3.53 Bn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 9.85 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 24.21 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 3.57 Bn |
| 10 | Lensar | 70.05 Mn | 72.73 Mn | 6.38 Mn | 40.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40.83 Mn |
| Dec 31, 2025 | 82.76 Mn |
| Sep 30, 2025 | 81.42 Mn |
| Jun 30, 2025 | 32.44 Mn |
| Mar 31, 2025 | 80.70 Mn |
| Dec 31, 2024 | 17.80 Mn |
| Sep 30, 2024 | 13.20 Mn |
| Jun 30, 2024 | 23.72 Mn |
| Mar 31, 2024 | 20.02 Mn |
| Dec 31, 2023 | 13.95 Mn |
| Sep 30, 2023 | 20.16 Mn |
| Jun 30, 2023 | 24.19 Mn |
| Mar 31, 2023 | 12.52 Mn |
| Dec 31, 2022 | 13.69 Mn |
| Sep 30, 2022 | 12.22 Mn |
| Jun 30, 2022 | 13.80 Mn |
| Mar 31, 2022 | 10.44 Mn |
| Dec 31, 2021 | 11.52 Mn |
| Sep 30, 2021 | 10.97 Mn |
| Jun 30, 2021 | 10.78 Mn |